Becton Dickinson (BDX) Q1 2025 10-Q Quarterly Report
Filed: May 1, 2025Period ending Mar 31, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR Becton Dickinson (BDX) 10-Q quarterly report for Q1 2025, filed with SEC EDGAR on May 1, 2025 for the fiscal period ending Mar 31, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Becton Dickinson Q1 2025 10-Q Analysis
Risk Factors
- • New risk: U.S. tariffs and countermeasures may reduce global trade, impact supply chain costs, particularly affecting operations in China
- • Updated legal risk: Increased global enforcement of anti-corruption laws elevates risk of fines linked to international operations under Foreign Corrupt Practices Act
Becton Dickinson Q1 2025 Quarterly FinancialsXBRL
Revenue
$5.3B
▲ +4.5% YoY▲ +2.0% QoQ
Net Income
$308M
▼ -42.6% YoY▲ +1.7% QoQ
Operating Margin
10.4%
▼ -417bp YoY▲ +161bp QoQ
Net Margin
5.8%
▼ -480bp YoY▼ -2bp QoQ
EPS (Diluted)
$1.07
▼ -42.2% YoY▲ +2.9% QoQ
Operating Cash Flow
$164M
▼ -68.1% YoY▼ -76.3% QoQ
Source: XBRL data from Becton Dickinson Q1 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Becton Dickinson Quarterly Reports
Get deeper insights on Becton Dickinson
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.